two trials is successful and the other trial has a treatment effect that points in the same direction,
a third phase III trial will be conducted with a sample size of N3 = N3(ymin), which depends on an assumed minimal clinical relevant effect (<code>ymin</code>).
The third trial then has to be significant at level <code>alpha</code></p></li>
<li><p>If only one of the two trials is successful and the treatment effect of the other points in opposite direction or
if none of the two trials are successful, then 